StockNews.AI
SIBN
StockNews.AI
197 days

SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025

1. SI-BONE to report Q4 and FY 2024 results on February 24, 2025. 2. Company has over 115,000 procedures performed using their innovative technology. 3. Evidence includes two randomized controlled trials and 160 peer-reviewed publications. 4. Management conference call scheduled for February 24 at 1:30 PM PT.

Earnings
+5.29%Current Return
VS
+0.66%S&P 500
$17.0202/03 04:14 PM EDTEvent Start
$17.9202/04 09:59 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

The upcoming earnings report may signal continued growth and investor interest. Similar past announcements have positively influenced stock prices as market responds to growth potential.

How important is it?

The financial results and accompanying call are critical for SIBN investors. Positive results can enhance investor confidence and drive stock appreciation.

Why Short Term?

The earnings report will have an immediate effect on stock sentiment. Past earnings calls led to significant price movements within weeks of the announcements.

Related Companies

SIBNNASDAQ
February 03, 2025 16:09 ET  | Source: SI-BONE, Inc. SANTA CLARA, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, February 24, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/xyxunb4k. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event. About SI-BONE, Inc. SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009, SI-BONE has supported over 4,300 physicians in performing a total of over 115,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 160 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, sacropelvic fixation and pelvic trauma. For additional information on the company or the products including risks and benefits, please visit www.si-bone.com. iFuse Bedrock Granite, iFuse-TORQ, iFuse TORQ TNT, SI-BONE, and iFuse INTRA are registered trademarks of SI-BONE, Inc. ©2025 SI-BONE, Inc. All Rights Reserved. Investor Contact: Saqib Iqbal, investors@si-bone.com

Related News